OCUL 8.78 (-1.57%)
US67576A1007BiotechnologyBiotechnology

Ocular Therapeutix (OCUL) Stock Highlights

8.78 | -1.57%
2024-11-21 03:08:45
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Statistics

Range Today
8.57 8.98
Volume Today 797.7K
Range 1 Year
2.14 11.77
Volume 1 Year 456.92M
Range 3 Year
2 11.77
Volume 3 Year 900.8M
Range 10 Year
2 44.19
Volume 10 Year 2.11B

Highlights

Market Capitalization 1.73B (small)
Floating Shares 118.91M
Current Price 8.78
Price To Earnings -9.92
Price To Revenue 22.03
Price To Book 4.57
Earnings Per Share -1.09
Payout Ratio 0%

Performance

Latest -1.57%
1 Month -23.52%
3 Months +0.92%
6 Months +42.76%
1 Year +285.09%
3 Years +31.44%
5 Years +212.46%
10 Years -44.29%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.